Ovarian Cancer: KOL Insight

Maximum Purchase:
1 unit
Publication Date:
February 2015
Adding to cart… The item has been added

Ovarian Cancer: KOL Insight, A new era of targeted therapy provides leading clinician insights on new ovarian cancer (OC) drugs at a time of significant change in the therapy landscape.

Why This Report is Essential

KOL Views: Products

A number of targeted therapies including VEGF, angiopoietin, PARP and MEK inhibitors along with immunotherapeutics are in late-stage trials for the treatment of OC. But how do KOLs think they will fit into the treatment algorithm, and what are the clinical benefits and disadvantages that will impact their use?

Of all the products vying for market share, the most excitement is being caused by AstraZeneca's PARP inhibitor Lynparza (olaparib), with many anticipating that the impressive PFS figures will see it become widely used for maintenance therapy in relapsed BRCA-mutation positive OC. Roche's Avastin is widely used off label in the US, but will sales be preserved despite the limitation of its recent FDA approval for only platinum-resistant recurrent ovarian cancer?

OC is a complex condition and niche opportunities for treating patient subgroups will create a wide portfolio of therapeutic options.

  • How, and in which settings, will clinicians use these new therapies?
  • What will influence their prescribing decisions?
  • Which product combinations are most favoured, and why?
  • Which products are most likely to be affected as the new treatment paradigm takes shape? What role will biomarkers play?

Ovarian Cancer: KOL Insight presents business-critical insights from 12 leading US and European KOLs for branded pharma and the drug discovery community. Find out what they think about current treatments and new therapies, and the competing benefits and challenges that influence their decisions.

VEGF Inhibitors
  • Avastin (bevacizumab; Roche/Genentech)
  • Nintedanib (Boehringer Ingelheim)
  • Cediranib (AZD2171; AstraZeneca)
Angiopoietin inhibitors
  • Trebananib (AMG 386; Amgen/Takeda)
PARP Inhibitors
  • Lynparza (olaparib; AstraZeneca)
  • Rucaparib (Clovis)
  • Niraparib (MK-4827; Merck & Co/Tesaro)
MEK Inhibitors
  • Binimetinib (MEK162; Array BioPharma/Novartis)
  • Mekinist (trametinib; GlaxoSmithKline)
  • CVac (MUC1 Dendritic Cell Vaccine; Prima BioMed)
  • Perjeta (pertuzumab; Roche/Genentech)
  • Farletuzumab (MORAb-003; Eisai)
  • Checkpoint inhibitors (AstraZeneca/Bristol-Myers Squibb/Merck/Pfizer)


Request Sample Pages

Key Benefits

  • Formulate effective strategies for product positioning and clinician communication
  • Map new treatment options to OC patient subgroups
  • Identify product attributes and patient characteristics that the KOLs think are the most important in terms of prescribing decisions
  • Discover which clinical trials the KOLs believe will have a significant impact on future treatment decisions and their likely outcomes
  • Evaluate the changing competitive landscape and identify solutions that aid KOLs in their practice

Request Sample Pages

Get Answers to Critical Questions

  • AstraZeneca’s highly anticipated PARP inhibitor Lynparza (olaparib) was first to market but how does it compare with upcoming competitors such as Clovis’ rucaparib and Merck & Co.’s niraparib?
  • How could Roche use the recent US approval of Avastin to widen its adoption in other settings?
  • What role will tolerability play in the novel MEK inhibitor race between GSK’s trametinib and Array Biopharma’s/Novartis’ binimetinib?
  • Prima BioMed’s CVac, Roche’s Perjeta and Eisai’s farletuzumab are all in Phase III trials. But will checkpoint inhibitors such as BMS’ Opdivo and Yervoy win out in the battle for immunotherapeutic dominance?
  • What role will biomarkers play in shaping the OC treatment landscape?
  • Could the combination of AstraZeneca’s VEGF inhibitor cediranib with its PARP inhibitor Lynparza herald a new chemotherapy free treatment regimen?

Top Takeaways

  • Detailed opinions of leading KOLs on current and expected treatments for OC and what they see as the critical advantages/disadvantages affecting their decision to prescribe
  • Important factors affecting the OC sector and identify key areas for strategic and tactical action
  • How current and new therapies will fit into the treatment paradigm
  • KOL attitudes to important clinical trials such as AURELIA, LUME-Ovar-1, ICON6, SOLO1, SOLO2, ARIEL 3, NOVA, MILO, GOG-0281, CAN-004, PENELOPE, and TRINOVA-2 and -3

Request Sample Pages

Key Opinion Leaders

North America

  • Ronald D. Alvarez, MD, professor and director of the Division of Gynecologic Oncology at the University of Alabama at Birmingham
  • Michael J. Birrer, MD, PhD, MS, Professor of Medicine, Harvard Medical School
  • James J. Hsieh, MD, PhD, Memorial Sloan Kettering Cancer Center, NY
  • Robert Burger, MD, FACS, Director of Clinical Research and Fellowship Program in Gynecologic Oncology, Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
  • Thomas Herzog, MD, FACOG, FACS, Clinical Director of the Barrett Cancer Center and Chair of the University of Cincinnati Cancer Institute
  • Bradley J. Monk, MD, FACOG, FACS, Director of the Division of Gynecologic Oncology, Vice Chair of the Department of Obstetrics and Gynecology, Professor at Creighton University of School of Medicine Phoenix Regional Campus and the University of Arizona College of Medicine Phoenix Branch
  • Krishnansu S. Tewari, MD, FACOG, FACS, Professor and Director of Research in the Division of Gynecologic Oncology at the University of California, Irvine


  • Isabelle Ray Coquard, MD, Professor of Medicine in Medical Oncology, President of the GINECO group, Université Claude Bernard, Lyon, France
  • Sandro Pignata, MD, PhD, Head of Uro-Gynecological Department, National Cancer Institute in Naples, Italy
  • Stan Kaye, MD, Retiree. Until recently was Head of the Division of Clinical Studies. Head of the Drug Development Unit, Institute of Cancer Research, London. Royal Marsden Hospital, UK
  • Christian Marth, MD, PhD, Director of the Department of Obstetrics & Gynecology, University Hospital Innsbruck, Austria
  • Nicholas Reed, MD, Consultant in Clinical Oncology, Beatson Oncology Centre, Glasgow, UK
  • Anonymous German KOL

Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, February 2015.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Request Sample Pages


Therapy Trends reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.